Sandoz growth strategy in Japanese market - … · a Novartis company Sandoz growth strategy in Japanese market - From Global Generics company perspective - IGPA Kyoto December 2012

a Novartis company

Sandoz growth strategy in Japanese market - From Global Generics company perspective -

IGPA Kyoto

December 2012

Junichi Nakamichi, Country Head, Sandoz K.K.

2 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Agenda

Sandoz overview

Leadership in differentiated generics

Sandoz strategy for Japan


Environment Patient needs Novartis portfolio

Sandoz is a Novartis Group Company

2011 sales USD billion

Full range of healthcare options

Innovative medicines

Prevention

Affordable options

Self-care

Pharmaceuticals

Sandoz – Generics

Consumer Health

(OTC, Animal Health)

Vaccines and

Diagnostics

Eye Care

(Alcon, CIBA VISION)

32.5

9.5

4.6

2.0

10.0


Novartis’ mission is to care for and cure patients

In 2011, Novartis treated and protected more than

1 billion patients

around the world with our products

and Sandoz medicines reached over

400 million patients


Sandoz sales grew at double-digit since 2009

Sandoz third-party sales USD billion

+12% CAGR

2009

9.5

2010

8.6

2011

7.5


2009

1940 1960 1980 2000

1886 Biochemie

1946

1986

1992

1946 Amifarma

Sabex

Durascan

Roferm

Azupharma

Servipharm

Geneva

Multipharma

Rolab

CIBA

Geigy

1859

1758

Hoechst fermentation

Wyeth penicillins, Invamed, SBPA

BASF Generics, Grandis, Labinca

Apothecon, Lagap, Aventis cephalosporins

2003

2010

Sandoz roots in high-quality medicines run deep

2010

2012

2011


Sandoz operates in 140 countries globally

Subsidiaries

Representative

offices

* Sample Sandoz manufacturing and development sites.

Production*

Development*

Wilson

Cambe/

Taboao

Gebze Turbhe

Strykow

Zhongshan

Kaminoyama

Barleben

Boucherville

Broomfield

Unterach

Kalwe

Holzkirchen Rudolstadt

Kundl /

Schaftenau

Ljubljana / Mengeš

Spartan Jakarta

Candelaria


Agenda


Sandoz overview



Sandoz has an industry-leading breadth of technologies

Inhalers

Patches/

transdermals/

thin films

Innovative

solid

formulations

Implants

Biosimilars

API Cytotoxics

Hormones

Lyophilization

Injectables

Ophthalmics

Dermatology

http://images.google.ch/imgres?imgurl=http://www.nuh.com.sg/healthinfo/images/dscf0009.jpg&imgrefurl=http://www.nuh.com.sg/healthinfo/asthma/3_anti_asthma_medic.asp&start=9&h=200&w=200&sz=10&tbnid=rZtrPORaHD8_wM:&tbnh=104&tbnw=104&hl=en&prev=/images?q=Inhalers&um=1&hl=en&rlz=1T4GGLJ_enGB272GB273&sa=N&um=1&usg=__zH8nYBHkqHXMSIRLqmJNl5szhMo=

http://images.google.ch/imgres?imgurl=http://www.patentdocs.us/photos/uncategorized/2007/07/29/0100186108805.jpg&imgrefurl=http://www.patentdocs.net/patent_docs/2007/07/index.html&start=1&h=216&w=288&sz=17&tbnid=kGhVejln36Qi0M:&tbnh=86&tbnw=115&hl=en&prev=/images?q=Metoprolol+succinate+launch&um=1&hl=en&rlz=1T4GGLJ_enGB272GB273&sa=N&um=1&usg=__SCeBrISR-KHvL0wewQjzkfCXl6k=

http://images.google.ch/imgres?imgurl=http://www.bioforum.org.il/Uploads/Courses/27.jpg&imgrefurl=http://www.bioforum.org.il/Course.aspx?cid=27&start=2&h=227&w=325&sz=38&tbnid=POo8TFNxCghY3M:&tbnh=82&tbnw=118&hl=en&prev=/images?q=Active+Pharmaceutical+Ingredients&gbv=1&um=1&hl=en&rlz=1T4GGLJ_enGB272GB273&um=1&usg=__325uUVLMHWStcAXFxzs12yoOA5s=


Sandoz is the global pioneer in safe, effective biosimilars

2006 2007 2009

• First biosimilar in EU;

approved May 2006

• Broad global launch (e.g.,

US, Japan & LATAM)

somatropin

• Introduced for nephrology

in Oct. 2007

• First EPO biosimilar in EU

• Launched in Oncology

(2009 & 2010)

erythropoietin

• Feb. 2009 EU approval

• Growing rapidly across

EU markets

G-CSF

2008 2010


Sandoz is the world leader in developing, manufacturing and commercializing biosimilars

Commercial experience:

Broad global presence (marketing in ~50 countries)

Manufacturing experience:

Producing recombinant proteins since 1980

Full range of capabilities

Development expertise:

Pioneer – developing biosimilars since 1996

8-10 molecules in development, including mAbs


Agenda



Sandoz overview


Sandoz Japan provides “Added-value” and “Trust through Reliability” by leveraging global assets

API

FDF* products

Quality standards

Value-added products

• Onco-safe

• Pre-mixed /

liquid vials

Addressing customer needs

Difficult-to-make

Biosimilars

Globally integrated

drug safety

management

system

*Finished dosage forms

Differentiation

Pursuing economies of scale People synergies

Japan experts

Diversified multi-

culture

Talent


API

FDF*

AP

I so

urc

ing

Develo

pm

en

t

FD

F

Pro

du

ctio

n

Ins

pe

ctio

n /

Pa

ck

ag

ing

Lo

cal requ

iremen

ts

Fo

r registratio

n

Ma

rketin

g

Glo

bal

Jap

an

Support Partial Support Sharing

reports

QA Sales PMS

Business model deploying global scale merit - Concept

*Finished dosage forms


“We will be the main provider of high quality,

affordable medicines helping secure long-term

access to healthcare for people around the world.”

Sandoz mission

Sandoz growth strategy in Japanese market - … · a Novartis company Sandoz growth strategy in Japanese market - From Global Generics company perspective - IGPA Kyoto December 2012

Documents